KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) EBIT Margin: 2017-2025

Historic EBIT Margin for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Sep 2025 value amounting to 8.97%.

  • Amneal Pharmaceuticals' EBIT Margin fell 368.00% to 8.97% in Q3 2025 from the same period last year, while for Sep 2025 it was 12.19%, marking a year-over-year increase of 519.00%. This contributed to the annual value of 8.92% for FY2024, which is 39.00% up from last year.
  • Amneal Pharmaceuticals' EBIT Margin amounted to 8.97% in Q3 2025, which was down 41.67% from 15.37% recorded in Q2 2025.
  • Amneal Pharmaceuticals' 5-year EBIT Margin high stood at 15.37% for Q2 2025, and its period low was -35.51% during Q2 2022.
  • In the last 3 years, Amneal Pharmaceuticals' EBIT Margin had a median value of 12.20% in 2023 and averaged 9.80%.
  • As far as peak fluctuations go, Amneal Pharmaceuticals' EBIT Margin slumped by 4,805bps in 2022, and later skyrocketed by 4,888bps in 2023.
  • Over the past 5 years, Amneal Pharmaceuticals' EBIT Margin (Quarterly) stood at 2.08% in 2021, then skyrocketed by 383bps to 5.91% in 2022, then plummeted by 361bps to 2.30% in 2023, then skyrocketed by 807bps to 10.38% in 2024, then slumped by 368bps to 8.97% in 2025.
  • Its EBIT Margin was 8.97% in Q3 2025, compared to 15.37% in Q2 2025 and 14.43% in Q1 2025.